63 results
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome
06 Oct 2020
Reviewer
Timing of oral P2Y12 inhibitor administration in non-ST elevation acute coronary syndrome
08 Sep 2020
What do you do in your daily practice: Do you use routine pre-treatment in NSTEMI patients? Have you modified your practice based on the new ESC guidelines?
Reviewer
Randomised comparison of the polymer-free biolimus-coated BioFreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with PCI: the SORT OUT IX Trial
03 Jul 2020
While investigations testing differences in efficacy and safety between drug-eluting stents according to the characteristics of the coating – durable, bioresorbable, or polymer-free – have shown mixed results, several studies have highlighted the benefit of implanting a device with thinner strut.
Reviewer
Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome : the TICO randomised clinical trial
02 Jul 2020
The outstanding results of the TICO trial have to be interpreted in light of a number of considerations and the generalisability of its results in other contexts requires further analysis.
Reviewer
Ticagrelor or prasugrel in patients with acute coronary syndromes - ISAR-REACT 5
06 Apr 2020
The objective of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial is to test the hypothesis that the ticagrelor strategy is superior to prasugrel strategy in patients with ACS in a composite clinical outcomes.
Reviewer
Reviewer
Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography
17 Feb 2020
EARLY ACS was a randomised control trial assessing early versus delayed use of eptifibatide in patients presenting with NSTE-ACS and high-risk features. In this subanalysis, the authors evaluate the association between morphine and ischaemic events in patients pre-treated with clopidogrel.
Reviewer
Reviewer
Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting
10 Nov 2019
One of the most discussed limitations of GLOBAL-LEADER is the lack of event adjudication so that the rate of MI, bleeding or stent thrombosis between the two groups were unknown. In this study, events were adjudicated in those patients from the 20 top-enrolling participating sites.
Reviewer
Ticagrelor with or without aspirin in high-risk patients after PCI
07 Oct 2019
The TWILIGHT trial was designed to test the hypothesis that in patients undergoing PCI who are at high risk for ischemic or hemorrhagic complications and who have completed a 3-month course of DAPT with ticagrelor plus aspirin, continued treatment with ticagrelor monotherapy would be superior to ticagrelor...
Reviewer
Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention
09 Jul 2019
Results of the SMART-CHOICE randomized clinical trial
Reviewer
Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI
09 Jul 2019
Results of the STOPDAPT-2 randomized clinical trial
Reviewer
